This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           October 08, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


Ovarian cancer often arises from precursor endometriosis
The Oncology Report
Gynecologists, general surgeons and primary care physicians now share an unprecedented opportunity to put a major dent in the incidence of ovarian cancer, according to Dr. Farr R. Nezhat. Mounting evidence suggests that identification and complete surgical removal of endometriosis reduce the risk of several histologic types of ovarian cancer. So when a woman visits her primary care physician for pelvic pain or vaginal bleeding that might be due to endometrial pathology, or a general surgeon finds asymptomatic endometriosis during pelvic surgery, these encounters provide an opportunity for preventive intervention, explained Dr. Nezhat in Lancet Oncology.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Practice Survey deadline extended to Oct. 13
Full and Candidate Members: The deadline has been extended to Oct. 13 to take SGO’s Practice Survey. If you missed the email with your personal link to the survey, please click here. Robust results may help you negotiate a higher salary. Those who complete the survey will receive the 2015 State of the Subspecialty report at no charge.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Experimental HPV vaccine could boost cervical cancer protection worldwide
Cancer Research UK
A “‘next generation’” vaccine that protects against nine types of human papillomavirus (HPV) may prevent even more cervical cancers than the current immunization program, according to an analysis published in Cancer Epidemiology, Biomarkers and Prevention by an international team of researchers. The new vaccine, currently under investigation by pharmaceutical company Merck, covers nine types of HPV, which between them account for at least 85 percent of cervical abnormalities that can develop into cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.


Drug helps prevent chemo-induced nausea/vomiting
Cancer Network
The drug rolapitant given in combination with granisetron/dexamethasone more effectively prevented chemotherapy-induced nausea and vomiting than granisetron/dexamethasone alone in patients undergoing treatment with cisplatin-based chemotherapy, results of a new study shows in Annals of Oncology. Rolapitant is a novel antagonist of the NK-1 receptor. Patients treated with rolapitant had significant improvements in nausea and vomiting without affecting other quality-of-life indicators.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Cancer centers should integrate palliative care to ensure dignity at end of life
Cancer Network
Cancer patients on palliative care wards were more likely to experience a dignified death than patients in other parts of cancer centers, suggesting that palliative services should be integrated into all cancer care, a recent study found. In a survey of physicians and nurses working in hospitals at 10 cancer centers in Germany, almost all participants who worked on palliative care wards (95 percent) reported that patients died with dignity in their units, compared with 57 percent of respondents overall. Half of all respondents said they rarely had enough time to care for dying patients, and less than 20 percent felt prepared to care for the dying. The results were published online in Cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Work for the best
We are seeking a gyn-oncologist to join our growing health system in Springfield, Mo. Our clinic has on-site lab and radiology services, access to a da Vinci® surgical robot and a strong support staff. For more information about this opportunity at our physician owned and operated clinic, call 1-800-869-4201. MORE
Exceptional Care, Close to Home

21st Century Oncology – the nation’s largest cancer treatment network and global leader in cancer care – providing integrated clinical teams treating patients collaboratively to improve outcomes.


First pictures of BRCA2 protein show how it works to repair DNA
Science Daily
Scientists have taken pictures of the BRCA2 protein for the first time, showing how it works to repair damaged DNA. The findings, in Nature Structural & Molecular Biology, showed that each pair of BRCA2 proteins binds two sets of RAD51 that run in opposite directions. This allows it to work on strands of broken DNA that point in either direction. They also show that BRCA2's job is to help RAD51 form short filaments at multiple sites along the DNA, presumably to increase the efficiency of establishing longer filaments required to search for matching strands.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


The cost of cancer drugs
CBS News
Cancer is so pervasive that it touches virtually every family in this country. More than one out of three Americans will be diagnosed with some form of it in their lifetime. And as anyone who's been through it knows, the shock and anxiety of the diagnosis is followed by a second jolt: the high price of cancer drugs. They are so astronomical that a growing number of patients can't afford their co-pay, the percentage of their drug bill they have to pay out-of-pocket. This has led to a revolt against the drug companies led by some of the most prominent cancer doctors in the country.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Two more studies say FDA is bad at regulating medical devices
The Philadelphia Inquirer via Redding
Two new studies add to a mountain of evidence that the U.S. Food and Drug Administration has done a poor job of making sure medical devices are safe. The studies, in the current issue of JAMA Internal Medicine, are accompanied by commentaries that point out that the agency recognizes the need for change and is in the midst of improving the device approval system.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Oct. 1, 2014
Sept. 24, 2014
Sept. 17, 2014
Sept. 3, 2014

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063